April 11, 2026
(Saturday)
Super Exciting 🥳… The man building one of the world’s most powerful AIs just told the world where the next great wealth-creation wave is coming from — and it isn’t tech.
On Nikhil Kamath’s People by WTF podcast, Dario Amodei — CEO of Anthropic, creator of Claude, and one of TIME magazine’s 2025 “Architects of AI” — was asked which stock he would invest in, if he has $100.
His answer:
Translation for investors: the AI revolution isn’t just about chatbots…. The compounders of the next decade may very well be sitting in the biotech corner of the market — small, under-followed, and about to be supercharged by AI-driven discovery.
The man building the AI is telling us where to look. We should listen.
▶️ Watch the exact 5-minute segment here
Dario Isn’t Saying This Alone — Three More Giants Are Already Putting Their Money Where His Mouth Is
If Dario Amodei were the only voice saying “biotech is about to have its AI moment”, it would still matter. But he isn’t. Three of the most consequential figures in technology and venture capital — a Nobel laureate, the CEO of OpenAI, and Silicon Valley’s most influential AI investor — are independently making the same call, and backing it with their own capital.
Voice 1 · The Nobel Laureate
Sir Demis Hassabis — DeepMind CEO, 2024 Nobel Prize in Chemistry
Hassabis won the 2024 Nobel Prize in Chemistry for AlphaFold — the AI system that solved a 50-year-old grand challenge in biology by predicting the 3D structure of virtually every protein known to science. When CBS 60 Minutes asked him whether AI could eventually eradicate every human disease, he didn’t hedge.
Source: CBS 60 Minutes interview · Nobel Prize 2024 announcement
Voice 2 · The Founder Putting His Net Worth On The Line
Sam Altman — CEO, OpenAI
The CEO of the company that gave the world ChatGPT didn’t just talk about biotech being the next wave — he wrote the largest personal cheque of his life into it. Altman quietly funded the entire $180 million seed round of Retro Biosciences, a longevity startup using AI to extend human lifespan. In January 2026, he doubled down by joining Retro’s $1 billion Series A.
In other words: the man who built the world’s most valuable AI company looked at his entire personal fortune and decided two industries were worth betting it all on. One was fusion energy. The other was biotech.
Sources: MIT Technology Review · Fortune ($1B Series A)
Voice 3 · Silicon Valley’s Most Influential AI Investor
Vinod Khosla — Founder, Khosla Ventures · Early backer of OpenAI
Khosla wrote OpenAI’s first $50 million cheque when nobody believed in it. He called the internet, mobile, and the cloud — all early. His current obsession? AI-powered medicine and biology. He has called it the most consequential platform shift in his entire career.
Khosla has spent the last three years steering his fund’s largest cheques into AI-driven drug discovery, AI doctors, and genomics. When the man who funded OpenAI starts moving capital into biotech, the smart money pays attention.
Source: TIME interview · Advisory Board
The Convergence: Four Independent Voices, One Single Message
Step back for a moment and look at what just happened on the world stage. Four people who almost never agree on anything — the CEO of Anthropic, the CEO of DeepMind, the CEO of OpenAI, and the most consequential venture investor of his generation — are all independently saying the same thing, in the same calendar year, with their own money on the line:
The Shared Thesis
“The single biggest opportunity unlocked by AI is not chatbots or coding assistants — it is biology. We are about to compress a century of biological progress into a single decade.”
When four people of this calibre converge on the same idea at the same time, history says it pays to take notice. The internet had its convergence moment in 1995. Mobile had it in 2008. The cloud had it in 2011. Each of those convergence moments minted multibaggers for investors who positioned themselves before the broader market caught on.
What This Means for the Indian Long-Term Investor
Indian capital markets have a rare habit of catching global themes after they have already played out in the West. By the time the average Indian investor woke up to the cloud, AWS was already a $100 billion business. By the time most retail investors heard about AI, NVIDIA had already become the world’s most valuable company.
The biotech-meets-AI wave is different — it is still in its earliest, most under-followed stage in India. The Indian biotech, pharma API, contract research, fermentation, and specialty bioscience corner of the market is still trading at modest valuations relative to what is coming. There is a real, narrow window in which patient long-term investors can identify the highest-quality, owner-managed, debt-free, cash-generating Indian businesses sitting at the intersection of biology and the AI tailwind — before the rest of the market figures out what Dario, Hassabis, Altman, and Khosla have already figured out.
This is exactly the kind of long-horizon, fundamentals-first opportunity that value investing in India was built for. Not speculation. Not chasing tickers. Quietly identifying high-quality compounders early, holding them through cycles, and letting time and a structural global tailwind do the heavy lifting.
📢 Join Our Telegram Channel
Get daily value investing lessons, stock analysis & Titan Biotech updates — delivered straight to your phone!
✈️ Join @longtermequityy on Telegram
🔔 Free • No spam • Value investing insights daily
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
